Current dosage and schedule issues in the development of paclitaxel (Taxol) - PubMed (original) (raw)
Review
. 1993 Aug;20(4 Suppl 3):31-9.
Affiliations
- PMID: 8102016
Review
Current dosage and schedule issues in the development of paclitaxel (Taxol)
S G Arbuck et al. Semin Oncol. 1993 Aug.
Abstract
Basic questions regarding optimal dose and schedule of anticancer drug administration frequently persist long after regulatory approval and commercial availability of a drug. For paclitaxel (TAXOL), these questions were considered early in drug development. This paper reviews the available preclinical studies that assessed different drug concentrations and durations of drug exposure. The current status of clinical trials designed to help resolve these issues is also reviewed.